請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45377
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲(Fe-Lin Lin Wu) | |
dc.contributor.author | Chia-Chi Chen | en |
dc.contributor.author | 陳佳其 | zh_TW |
dc.date.accessioned | 2021-06-15T04:16:56Z | - |
dc.date.available | 2013-03-12 | |
dc.date.copyright | 2010-03-12 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-12-28 | |
dc.identifier.citation | 1. Nahata, M.C. and C. Taketomo, Pediatrics, in Pharmacotherapy: a pathophysiologic approach, J.T. Dipiro, et al., Editors. 2008, McGraw-Hill: New York. p. 47-56.
2. Shirkey, H.C., Therapeutic orphans- everybody's business. Drug Intelligence, 1968. 2: p. 323. 3. Shirkey, H., Editorial comment: therapeutic orphans. Pediatrics, 1999. 104(3): p. 583. 4. “Therapeutic orphans” and the package insert. Pediatrics, 1970. 46(5): p. 811-812. 5. Pandolfini, C. and M. Bonati, A literature review on off-label drug use in children. European Journal of Pediatrics, 2005. 164: p. 552-558. 6. Reflection paper: Formulatios of choice for the paediatric population. 2006, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA): London. p. 1-45. 7. Wu, F., et al., Quality assurance in dispensing pediatric oral medication. Journal of the Clinical Pharmacy Association, 1993. 2(2): p. 123-138. 8. Yang, Y.-H.K., et al., Stability of furosemide, nadolol and propranolol hydrochloride in extemporaneously compounded powder packets from tablets. The Chinese Pharmaceutical Journal, 2000. 52: p. 51-58. 9. Lin, T.-R., et al., Content uniformity of captopril, furosemide, nadolol and propranolol hydrochloride powder packets extemporaneously compounded from tablets. The Chinese Pharmaceutical Journal, 2000. 52(1): p. 59-68. 10. 林攸美, 磨粉分包作業之品質及小兒用藥指導之成效探討, in 藥學研究所. 2001, 台北醫學大學: 台北市. p. 1-87. 11. Preventing pediatric medication errors. [The Joint Commission. Sentinel Event Alert.] 2008 [Accessed; Available from: http://www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_39.htm. 12. Strickley, R.G., et al., Pediatric drugs--a review of commercially available oral formulations. Journal Of Pharmaceutical Sciences, 2008. 97(5): p. 1731-1774. 13. WHO, Promoting safety of medicines for children. 2007. p. 1-62. 14. Guidance on E 11 clinical investigation of medicinal products in pediatric population; Notice. 2000, International Conference on Harmonisation. 15. Taketomo, C.K., J.H. Hodding, and D.M. Kraus, Definition of age group terminology, in Pediatric dosage handbook. 2008, Lexi-Comp: Hudson. p. 17. 16. Kliegman, R.M., et al., Nelson Textbook of Pediatrics. 2007. 17. Luedtke, S., M. Haase, and M. Condren, Pediatric considerations, in Applied therapeutics: the clinical use of drugs, M.A. Koda-Kimble, et al., Editors. 2009, Lippincott Williams & Wilkins. p. 93-1~93-22. 18. Shirkey, H.C., Therapeutic orphans. Journal of Pediatrics, 1968. 2: p. 119-120. 19. Blumer, J.L., Off-label uses of drugs in children. Pediatrics, 1999. 104(3): p. 598. 20. Cote, C.J. and R.E. Kauffman, Is the `therapeutic orphan' about to be adopted?, in Pediatrics. 1996. p. 118. 21. Wilson, J.T., An update on the therapeutic orphan. Pediatrics, 1999. 104(3): p. 585. 22. Cuzzolin, L., A. Zaccaron, and V. Fanos, Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundamental & Clinical Pharmacology, 2003. 17(1): p. 125-131. 23. Turner, S., et al., Unlicensed and off label drug use in paediatric wards: prospective study. British Medical Journal, 1998. 316: p. 343-345. 24. Barbosa Santos, D., et al., Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. European Journal Of Clinical Pharmacology, 2008. 64: p. 1111-1118. 25. Neubert, A., et al., Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey. Pharmacological Research, 2008. 58(5-6): p. 316-322. 26. Conroy, S., et al., Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (Clinical Research Ed.), 2000. 320(7227): p. 79-82. 27. To err is human. Building a safer health system., L.T. Kohn, J.M. Corrigan, and M.S. Donaldson, Editors. 1999, Institute of Medicine, National Academy Press: Washington DC. 28. Leape LL, et al., The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med, 1991. 324(6): p. 377-384. 29. Bates, D.W., et al., Relationship between medications and adverse drug events. Journal of General Internal Medicine, 1995. 10: p. 199-205. 30. What is a medication error? [Accessed 2009 Aug 30]; Available from: http://www.nccmerp.org/aboutMedErrors.html. 31. Hicks, R.W., S.C. Becker, and D.D. Cousins, Harmful medication errors in children: A 5-year analysis of data from the USP’s MEDMARXR Program. Journal of Pediatric Nursing, 2006. 21(4): p. 290-298. 32. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. American Journal of Health-System Pharmacy, 1995. 52: p. 417-419. 33. Leape, L.L., Preventing adverse drug events. American Journal of Health-System Pharmacy, 1995. 52: p. 379-382. 34. Cuzzolin, L., A. Atzei, and V. Fanos, Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opinion on Drug Safety, 2006. 5(5): p. 703-718. 35. Turner, S., et al., Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr, 1999. 88: p. 965-968. 36. Horen, B., J.-L. Montastruc, and M. Lapeyre-Mestre, Adverse drug reactions and off-label drug use in paediatric outpatients. British Journal of Clinical Pharmacology, 2002. 54(6): p. 665-570. 37. Neubert, A., et al., The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety: An International Journal Of Medical Toxicology And Drug Experience, 2004. 27(13): p. 1059-1067. 38. Kaushal, R., et al., Medication errors and adverse drug events in pediatric inpatients. JAMA, 2001. 285(16): p. 2114-2120. 39. Holdsworth, M.T., et al., Incidence and impact of adverse drug events in pediatric inpatients. Archives Of Pediatrics & Adolescent Medicine, 2003. 157(1): p. 60-65. 40. Takata, G.S., et al., Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals. Pediatrics, 2008. 121(4): p. e927-935. 41. Preventing pediatric medication errors. 2008, The Joint Commission. 42. Allen, L.V., Extemporaneous prescription compounding, in Remington : the science and practice of pharmacy, R. Hendrickson, Editor. 2006, Lippincott Williams & Wilkins: Philadelphia. p. 1903-1912. 43. The United States Pharmacopeia. 2009. 44. Hawkins, B., ed. Best practices for hospital & health-system pharmacy: position & guidance documents of ASHP / American Society of Health-System Pharmacists. 2007-2008 ed., ASHP (American Society of Health-System Pharmacists): Bethesda, Maryland. 45. Morris, A.M., et al., National survey of quality assurance activities for pharmacy-compounded sterile preparations. American Journal Of Health-System Pharmacy: AJHP: Official Journal Of The American Society Of Health-System Pharmacists, 2003. 60(24): p. 2567-2576. 46. Treadway, A.K., D. Craddock, and R. Leff, Practices of pharmacies that compound extemporaneous formulations. American Journal Of Health-System Pharmacy: AJHP: Official Journal Of The American Society Of Health-System Pharmacists, 2007. 64(13): p. 1403-1409. 47. Taketomo, C., Pediatric Dosage Handbook. 8th Edition ed. 2001-2002: LEXI-COMP INC. 48. Nahata, M.C., V.B. Pai, and T.F. Hipple, Pediatric drug formulations. 5th ed. 2004, Cincinnati: Hayvey Whitney Books Company. 1-6. 49. Nunn, T. and J. Williams, Formulation of medicines for children. British Journal of Clinical Pharmacology, 2005. 59(6): p. 674-676. 50. 中央健康保險局. [Accessed 2009 Aug 10]; Available from: http://www.nhi.gov.tw/. 51. 中央健康保險局. 健保用藥品項查詢. [Accessed 2009 Aug 20]; Available from: http://www.nhi.gov.tw/inquire/query1.asp?menu=1&menu_id=8&WD_ID=42. 52. Sanz, E., et al., Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). European Journal Of Clinical Pharmacology, 2004. 60(2): p. 127-134. 53. Dimri, S., et al., Drug use pattern in children at a teaching hospital. Indian Pediatrics, 2009. 46: p. 165-167. 54. WHO model list of essential medicines for children. 2007, World Health Organization (WHO). p. 1-30. 55. WHO model list of essential medicines for children. 2009, World Health Organization (WHO). p. 1-34. 56. 中央健康保險局, 2009全民健康保險簡介. 2009, 朱澤民. p. 1-56. 57. 內政部統計處. 內政統計年報. [Accessed 2009 Sep 01]; Available from: http://sowf.moi.gov.tw/stat/year/list.htm. 58. 行政院衛生署統計資料. [Accessed 2009 Sep 01]; Available from: http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=10238&class_no=440&level_no=1. 59. Free online searchable ICD-9-CM. 2009 [Accessed 2009 Aug 20]; Available from: http://icd9cm.chrisendres.com/. 60. 行政院衛生署. 藥物、醫療器材、化粧品許可證查詢作業. [Accessed 2009 Aug 20]; Available from: http://203.65.100.151/DO8180.asp. 61. WHO. Complete ATC index 2009. [Accessed 2009 Aug 20]; Available from: http://www.whocc.no/atcddd/. 62. 全民健康保險研究資料庫. [Accessed 2008 Oct 20]; Available from: http://w3.nhri.org.tw/nhird//index.htm. 63. DRUGDEX System. MICROMEDEX(R) Healthcare Series. 2009. 64. MARTINDALE - The Complete Drug Reference. 2009. 65. 行政院衛生署, 生長曲線圖. 1999. 66. 李秉穎. 小孩的正常生長曲線. 1999 [Accessed 2008 Oct 22]; Available from: http://olddoc.tmu.edu.tw/pinging/health/he10.htm. 67. 台灣諾和諾德. 兒童身高、體重生長曲線表. [Accessed 2008 Oct 22]; Available from: http://www.novonordisk.com.tw/documents/article_page/document/GrowthChart.asp. 68. 陳偉德, et al., 台灣地區兒童及青少年生長曲線圖:依健康體適能訂定之標準. 中台灣醫誌, 2003. 8(Supplement 2): p. S85-93. 69. WHO, WHO child growth standards, W.H.O. Department of Nutrition for Health and Development, Editor. 2006. 70. DiPiro, J.T., et al., eds. Pharmacotherapy. 7th ed. 2008, McGraw-Hill: New York. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45377 | - |
dc.description.abstract | 研究背景:
目前在台灣兒童藥物治療常面臨的問題,除了許多藥品缺乏兒童之適應症及建議劑量外,許多口服藥品缺乏兒童製劑,給藥前常必須進行劑型調整。台灣許多醫療院所對兒童開立處方時,將錠劑磨粉或將膠囊內容物取出分包,在這些操作過程中有許多潛在問題,而這樣的情形究竟是因為兒童製劑的缺乏還是其未被充分利用,值得探討。 研究目的: 本研究欲調查台灣目前有哪些口服兒童製劑,以及這些製劑在兒童族群門診實際被開方情況,以了解兒童用藥情形及可能面臨的問題。 研究材料與方法: 主要研究材料為中央健康保險局2009年7月公布之全民健康保險用藥品項資料,與國家衛生研究院提供全民健康保險研究資料庫之百萬人抽樣歸人檔中2005至2007年資料。 首先篩選適合年齡未滿12歲兒童族群使用之口服兒童製劑,需同時考量該製劑之藥品是否有兒童適應症、主成份是否有兒童劑量資訊、主成份含量是否適合兒童使用、劑型是否方便兒童使用、及製劑為單方或複方組成等條件,再由健保用藥品項所有健保給付之口服劑型製劑中,依上述條件逐一進行篩選,依兒童適用年齡切割為未滿6歲及6歲至未滿12歲兒童之兒童製劑,討論兒童製劑的組成及足夠性。 後續由健保資料庫之百萬人抽樣歸人檔,分析兒童族群門診就醫資料及處方中口服藥品的開方情形,包括兒童製劑在不同年齡兒童及不同特約別醫療院所使用情況、現有兒童製劑利用率、開方藥品與就醫診斷的相關性、固體劑型開立未滿1顆劑量之比例等,以了解目前兒童門診就醫及處方情形。 研究結果: 在9,268筆口服製劑的825種主成份及46種劑型中,經篩選共有3,077筆(33.20%)為適合未滿12歲兒童族群使用的兒童製劑,包括280種主成份(33.94%)及34種劑型(73.91%),其中適合未滿6歲兒童使用的則有1,620筆(17.48%),包括192種主成份(23.27%)及21種劑型(45.65%)。而這些兒童製劑依藥理分類以呼吸系統(如咳嗽及感冒、抗組織胺、阻塞性呼吸道疾病)、腸胃道及代謝(如胃酸相關疾病、功能性腸胃道疾病)、感染、神經系統、肌肉骨骼系統(如抗發炎及風濕)等類別之用藥品項為最多。 兒童門診處方部份,兒童就醫常見主診斷類別依序為呼吸系統疾病、消化系統疾病、徵候症狀及診斷欠明之各種病態,而最常見開方藥品類別也主要為呼吸系統與腸胃道及代謝等疾病之用藥。兒童製劑開方佔所有開方藥品的比例在未滿6歲兒童平均為21.18%(醫學中心、區域醫院、地區醫院、基層院所分別為63.02%、51.56%、45.46%、16.64%)、在6歲至未滿12歲兒童則為29.31%(醫學中心、區域醫院、地區醫院、基層院所分別為54.24%、50.15%、42.62%、27.30%),此比例明顯以基層院所最低;另外適當的兒童製劑品項中實際被開方利用者,僅佔所有品項的六成左右。醫師常開立的非兒童製劑藥品,其主成份大多皆有適當的兒童製劑可選擇。錠劑及膠囊的開方劑量未滿1顆者,在未滿6歲兒童平均比例為92.13%,而在6歲至未滿12歲兒童則為58.51%,其中非1/4或1/2顆之零散不易精確分割及量取劑量者即佔了一半以上,尤以基層院所最多。 結論: 台灣現有健保給付適合未滿12歲兒童的口服兒童製劑,其品項及主成份分別佔全部口服製劑的33.20%及33.94%,且這些製劑在各藥理分類所佔比例與兒童疾病診斷之分佈相當一致,表示兒童製劑符合兒童之用藥需求。但實際上兒童製劑佔門診的開方比例卻不到三成,尤其在基層院所最低,這代表許多兒童在用藥時是使用不適當的成份或者劑型含量。另外這些兒童製劑在兒童的利用率也不高,可知兒童製劑並未被充分利用。 | zh_TW |
dc.description.abstract | Background:
There are usually some problems of the pharmacotherapy in children in Taiwan. Many medicines lack pediatric indications and dosing information for children, and many oral formulations are not easy for children to take, so the dosage forms need to be modified before administration. In Taiwan, we usually pulverize the tablets or open the capsules to make powder packages for children, and there might be errors during each steps of the extemporaneous compounding. We need to know whether it is due to deficiency or low utilization of pediatric formulations. Objective: The availability and utilization of pediatric oral formulations in Taiwan were unknown. We wanted to investigate how many oral formulations are appropriate for children, and what the prescription patterns of these products are in Taiwan. Materials and Methods: The materials we used were the formula issued by the Bureau of National Health Insurance in July, 2009, as well as the claim data of the longitudinal database and registration datasets from the National Health Insurance Research Database between 2005 and 2007. The criteria of pediatric formulations appropriate for children younger than 12 years of age we used included whether there’re label indications and dosing information for children, as well as appropriate unit doses and dosage forms for them. We then screened oral pediatric formulations from the products with health insurance reimbursement based on these criteria. We devided them into formulations for children younger than 6 y/o and those for children 6-12 y/o, and then discussed the composition and sufficiency of these pediatric formulations. Then a retrospective study was performed. We analyzed the prescription patterns of outpatient children, including the prescribing rate and utilization of pediatric formulations, the correlation between the medications prescribed and the diagnoses of children, the rate of prescribed dosage less than 1 tablets/capsules, etc.. Results: 825 components and 46 dosage forms constituted all 9,268 oral formulations included in this study. There're 3,077 (33.20%) pediatric formulations for children younger than 12 y/o that contained 280 (33.94%) components and 34 (73.91%) dosage forms. 1620 of them (17.48%) were suitable for children younger than 6 y/o and these contained 192 (23.27%) components and 21 (45.65%) dosage forms. The most common pharmacological groups of these formulations were agents for respiratory system, alimentary tract and metabolism, antiinfectives, nervous system, and muscle-skeletal system. The main diagnoses of children were diseases of respiratory system, digestive system, and signs, symptoms and ill-defined conditions. And the most often prescribed agents were those used for respiratory system, and alimentary tract and metabolism. The prescribing rates of pediatric formulations were 21.18% in children younger than 6 y/o, and 29.31% in children between 6 and 12 y/o. The rate was significantly lower in local clinics than in other health institutes. Besides, only about 66% of all pediatric formulations were ever prescribed in children. There’re actually appropriate pediatric formulations for most main ingredients of the non-pediatric formulations prescribed. Many solid dosage forms were prescribed less than 1 tablet/capsule, and more than half of them were dosages other than 1/4 or 1/2 that made the accurate devision difficult. Conclusions: There're 33.20% oral formulations and 33.94% generic components suitable for children younger than 12 y/o. The distribution of the pharmacological groups of pediatric formulations and the diagnoses of children were pretty similar, which meant these met the usual needs of children. But the average prescribing rate of pediatric formulations was only about 20-30%, so many children got their medications with inappropriate components, doses, or dosage forms, especially in local clinics. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:16:56Z (GMT). No. of bitstreams: 1 ntu-98-R96451001-1.pdf: 1972426 bytes, checksum: 6d5d7281ce15318f33687ac7cd52134c (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 誌謝 ii
中文摘要 iii Abstract vi 目錄 ix 圖目錄 xi 表目錄 xii 第1章 前言 1 第2章 文獻回顧 3 2.1 小兒族群之年齡定義 3 2.2 兒童藥物治療面臨的問題 4 2.2.1 治療學的孤兒 4 2.2.2 藥品仿單外使用 5 2.2.3 小兒用藥相關問題 6 2.2.4 臨場調製 13 2.3 小兒製劑(Pediatric formulations) 16 2.3.1 小兒製劑的定義 16 2.3.2 理想的小兒製劑 17 2.3.3 小兒用藥的劑型選擇 17 2.3.4 相關法令及鼓勵措施 21 2.3.5 兒童處方分析研究 23 2.4 WHO兒童基本用藥清單 24 2.5 台灣全民健保及小兒門診就醫背景 27 第3章 研究目的 29 第4章 研究材料及方法 30 4.1 研究材料 30 4.1.1 全民健康保險用藥品項 30 4.1.2 全民健康保險研究資料庫基本資料檔及百萬承保抽樣歸人檔 31 4.2 研究方法 34 4.2.1 兒童製劑篩選 34 4.2.2 兒童族群門診處方分析 46 第5章 研究結果 52 5.1 兒童製劑篩選 52 5.1.1 兒童製劑篩選結果 52 5.1.2 兒童製劑品項分析 60 5.1.3 兒童製劑品項與WHO兒童基本用藥清單比較 70 5.2 兒童族群處方分析 78 5.2.1 處方基本分析 78 5.2.2 回歸分析 110 第6章 討論 113 6.1 兒童製劑定義 113 6.1.1 本研究兒童製劑定義 113 6.1.2 優良兒童製劑條件 114 6.2 兒童製劑篩選 115 6.2.1 兒童製劑篩選之意義 115 6.2.2 兒童製劑數目及組成 116 6.2.3 兒童製劑符合WHO建議兒童基本用藥 117 6.3 兒童族群處方分析 119 6.3.1 兒童處方開立藥品數及成份數 119 6.3.2 兒童製劑開方比例 120 6.3.3 非兒童製劑藥品開方 122 6.3.4 兒童診斷及開方藥品類別 123 6.3.5 固體劑型製劑需開方或磨粉分析 124 6.4 研究限制 126 6.4.1 兒童製劑篩選 126 6.4.2 兒童族群處方分析 128 第7章 結論 130 參考文獻 131 附錄1 兒童製劑篩選之各組條件及結果 136 附錄2 各藥品主成份之兒童製劑筆數與無兒童製劑之原因 138 附錄3 各組兒童製劑之主成份數分布 172 附錄4 各組兒童製劑之劑型數分布 173 附錄5 兒童製劑各藥理分類之主成份、劑型及品項數 174 附錄6 WHO兒童基本用藥清單中有口服兒童製劑之藥品及建議劑型含量(依是否有各組兒童製劑區分) 185 附錄7 WHO兒童基本用藥清單中口服之外建議劑型之藥品及劑型含量(依建議劑型區分) 193 | |
dc.language.iso | zh-TW | |
dc.title | 台灣兒童族群門診中口服兒童製劑使用情形 | zh_TW |
dc.title | Availability of Commercial Pediatric Oral Formulations and Their Utilization in Outpatient Prescriptions for Children in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何?芳(Yun-Fang Ho),高雅慧(Yea-Huei Kao) | |
dc.subject.keyword | 兒童,兒童製劑,全民健康保險,門診病人,處方型態,台灣, | zh_TW |
dc.subject.keyword | children,pediatric formulation,National Health Insurance Research Database,outpatient,prescription pattern,Taiwan, | en |
dc.relation.page | 197 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-12-29 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.93 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。